Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW69,800.00
+200.00 (+0.29%)
KR KSC Healthcare Medical - Pharmaceuticals
Address
Chong Kun Dang Building 3742
Seoul, SEO, KR
Seoul, SEO, KR
CEO
Young-Ju Kim
Website
ckdpharm.com
IPO
2013-12-06
ISIN KR7185750007
Description
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetics, antiviruses, beta-blockers, anti-hyperlipidemia, and others. The company was founded on May 7, 1941 and is headquartered in Seoul, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW69,800.00
+200.00 (+0.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
31.7K
Beta
-0.43
Float Shares
8.44M
Free Float %
64.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.13% | -1.37% | -7.35% | -14.99% | -9.26% | -4.11% | -8.31% | -0.64% | -26.04% | +2.45% | +62.93% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
69,800.00
DCF (Unlevered)
144,413.33
+106.9%
DCF (Levered)
79,378.14
+13.7%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.24
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +7.4%+6.7% Q1'26: +11.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +24.4%-28.8% Q1'26: +8.8% (vs Q1'25)
-
FCF margin Drug Manufacturers - Specialty & Generic: +39.1%+0.2% Q1'26: -10.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +12.5%+4.8% Q1'26: +3.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +7.4%+7.4% ★ Q1'26: +4.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.5% ★ Q1'26: +4.7% (vs Q1'25)
-
Debt / EBITDA Drug Manufacturers - Specialty & Generic: -0.04×2.93× ★ Q1'26: 3.59× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
592.49B
est: 589.95B (+0.4%)
|
831.99B
est: 827.95B (+0.5%)
|
884.36B
est: 881.34B (+0.3%)
|
956.22B
est: 951.07B (+0.5%)
|
1.08T
est: 1.07T (+0.7%)
|
1.30T
est: 1.30T (0.0%)
|
1.34T
est: 1.33T (+1.1%)
|
1.49T
est: 1.47T (+1.6%)
|
1.67T
est: 1.65T (+0.9%)
|
1.59T
est: 1.56T (+1.4%)
|
1.69T
est: 1.69T (-0.1%)
|
1.87T
1.86T – 1.89T
+10.5% YoY
|
1.98T
1.85T – 2.09T
+5.5% YoY
|
2.02T
1.94T – 2.09T
+2.0% YoY
|
| EBITDA |
42.17B
est: 65.81B (-35.9%)
|
84.81B
est: 92.35B (-8.2%)
|
100.01B
est: 98.31B (+1.7%)
|
92.19B
est: 106.09B (-13.1%)
|
97.93B
est: 119.51B (-18.1%)
|
149.40B
est: 145.38B (+2.8%)
|
112.61B
est: 148.19B (-24.0%)
|
137.52B
est: 163.48B (-15.9%)
|
287.62B
est: 184.47B (+55.9%)
|
150.03B
est: 161.80B (-7.3%)
|
125.37B
est: 175.23B (-28.5%)
|
193.71B
192.56B – 195.81B
+10.5% YoY
|
204.45B
191.30B – 216.61B
+5.5% YoY
|
208.49B
201.07B – 215.91B
+2.0% YoY
|
| EBIT |
19.49B
est: 53.03B (-63.2%)
|
60.96B
est: 74.42B (-18.1%)
|
78.11B
est: 79.22B (-1.4%)
|
71.05B
est: 85.49B (-16.9%)
|
74.97B
est: 96.30B (-22.2%)
|
125.71B
est: 117.15B (+7.3%)
|
85.23B
est: 119.42B (-28.6%)
|
104.01B
est: 131.74B (-21.0%)
|
250.67B
est: 148.65B (+68.6%)
|
110.33B
est: 125.35B (-12.0%)
|
80.57B
est: 135.75B (-40.7%)
|
150.07B
149.17B – 151.69B
+10.5% YoY
|
158.39B
148.20B – 167.81B
+5.5% YoY
|
161.52B
155.77B – 167.26B
+2.0% YoY
|
| Net Income |
-6.77B
est: -5.71B (-18.5%)
|
40.95B
est: 38.73B (+5.7%)
|
53.81B
est: 51.50B (+4.5%)
|
42.40B
est: 43.26B (-2.0%)
|
53.88B
est: 49.51B (+8.8%)
|
91.63B
est: 86.96B (+5.4%)
|
42.72B
est: 50.41B (-15.3%)
|
80.95B
est: 79.50B (+1.8%)
|
212.52B
est: 210.92B (+0.8%)
|
109.07B
est: 105.49B (+3.4%)
|
77.83B
est: 79.38B (-2.0%)
|
72.31B
68.96B – 75.65B
-8.9% YoY
|
83.40B
76.54B – 104.44B
+15.3% YoY
|
84.05B
80.16B – 87.94B
+0.8% YoY
|
| SGA |
94.58B
est: 46.22B (+104.6%)
|
101.31B
est: 64.87B (+56.2%)
|
103.78B
est: 69.05B (+50.3%)
|
117.16B
est: 74.51B (+57.2%)
|
98.73B
est: 83.94B (+17.6%)
|
91.37B
est: 102.11B (-10.5%)
|
102.71B
est: 104.08B (-1.3%)
|
116.45B
est: 114.82B (+1.4%)
|
131.38B
est: 129.56B (+1.4%)
|
139.96B
est: 126.96B (+10.2%)
|
142.47B
est: 137.50B (+3.6%)
|
152.00B
151.09B – 153.64B
+10.5% YoY
|
160.43B
150.11B – 169.97B
+5.5% YoY
|
163.60B
157.77B – 169.42B
+2.0% YoY
|
| EPS |
-537.28
est: -431.42 (-24.5%)
|
3,249.02
est: 2,924.28 (+11.1%)
|
4,066.13
est: 3,888.29 (+4.6%)
|
3,382.95
est: 3,265.85 (+3.6%)
|
4,300.43
est: 3,737.57 (+15.1%)
|
7,317.59
est: 6,564.73 (+11.5%)
|
3,117.59
est: 3,805.64 (-18.1%)
|
6,608.77
est: 6,002.18 (+10.1%)
|
16,704.00
est: 15,922.96 (+4.9%)
|
8,206.52
est: 8,006.79 (+2.5%)
|
5,882.09
est: 6,025.20 (-2.4%)
|
5,488.50
5,234.40 – 5,742.19
-8.9% YoY
|
6,330.00
5,809.75 – 7,926.78
+15.3% YoY
|
6,379.67
6,084.30 – 6,674.55
+0.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-14 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-13 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-10 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-71.04B
OE per share TTM
-5,278.89
Owner's Yield
-6.48%
Maintenance CapEx ratio
368.46%
Maint CapEx / Avg PPE
21.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
33.05M
Shares Outstanding
13.18M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Young-Joo Kim | President, Chief Executive Officer & Chairman | 710M | male |
| Dong-ha Lee | Finance Manager & Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 185750.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
